Compare SCHW & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCHW | MRK |
|---|---|---|
| Founded | 1971 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.3B | 268.7B |
| IPO Year | 1987 | N/A |
| Metric | SCHW | MRK |
|---|---|---|
| Price | $101.90 | $111.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 14 |
| Target Price | $113.44 | ★ $114.86 |
| AVG Volume (30 Days) | 7.8M | ★ 13.3M |
| Earning Date | 01-21-2026 | 02-03-2026 |
| Dividend Yield | 1.07% | ★ 3.11% |
| EPS Growth | ★ 66.73 | 58.08 |
| EPS | 4.27 | ★ 7.56 |
| Revenue | $22,914,000,000.00 | ★ $64,235,000,000.00 |
| Revenue This Year | $24.59 | $1.97 |
| Revenue Next Year | $10.86 | $4.71 |
| P/E Ratio | $23.66 | ★ $14.49 |
| Revenue Growth | ★ 21.67 | 1.68 |
| 52 Week Low | $65.88 | $73.31 |
| 52 Week High | $104.98 | $112.90 |
| Indicator | SCHW | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 54.60 | 64.95 |
| Support Level | $99.60 | $106.93 |
| Resistance Level | $104.98 | $111.58 |
| Average True Range (ATR) | 2.25 | 2.66 |
| MACD | -0.29 | -0.20 |
| Stochastic Oscillator | 40.57 | 76.39 |
Charles Schwab is one of the largest retail-oriented financial-services companies in the US, with $11.6 trillion in client assets across its brokerage, banking, asset management, custody, financial advisory, and wealth-management businesses at the end of the third quarter. While best known for its retail brokerage offering, Schwab generates the lion's share of its revenue and profits through its Charles Schwab Bank and asset management segments. The firm is a dominant player in registered investment advisor custody, with over 40% market share, and has recently pushed into wealth management with robo-advisory, direct indexing, and other managed-investment solutions.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).